The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders

Neuroscience and Biobehavioral Reviews

Volumn 63, Issue , 2016, Pages 207-222

  Costales, Jesse ^a   Kolevzon, Alexander ^a,b,c  

^a Department of Psychiatry ^*  (United States)

^b Laboratory of Molecular Neuropsychiatry   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ASD; Autism spectrum disorder; Central nervous system disorders; CNS development; Fragile X syndrome; IGF 1; Insulin like growth factor 1; Neurodevelopmental disorders; Neurotrophic factors; Phelan McDermid syndrome; Rett syndrome

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RECOMBINANT PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; IGF1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; FRAGILE X SYNDROME; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHELAN-MCDERMID SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RETT SYNDROME; REVIEW; STRUCTURE ANALYSIS; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; METABOLISM; NERVE CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEURONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84959189375     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.01.001     Document Type: Review

References (180)

1. Adem A., Ekblom J., Gillberg P.G., Jossan S.S., Hoog A., Winblad B., Aquilonius S.M., Wang L.H., Sara V. Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J. Neural Transm. Gen. Sect. 1994, 97(1):73-84.
2. Aikin R., Maysinger D., Rosenberg L. Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets. Endocrinology 2004, 145(10):4522-4531. 10.1210/en.2004-0488.
3. Aleman A., Verhaar H.J., De Haan E.H., De Vries W.R., Samson M.M., Drent M.L., Van der Veen E.A., Koppeschaar H.P. Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab. 1999, 84(2):471-475. 10.1210/jcem.84.2.5455.
4. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am. J. Ment. Defic. 1985, 89(5):485-491.
5. American Psychiatric Association, A. P. A. D. S. M. T. F. (2013). Diagnostic and statistical manual of mental disorders: DSM-5. from. http://dsm.psychiatryonline.org/book.aspx%3Fbookid=556.
6. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23(2):185-188. 10.1038/13810.
7. Andersson I.K., Edwall D., Norstedt G., Rozell B., Skottner A., Hansson H.A. Differing expression of insulin-like growth factor I in the developing and in the adult rat cerebellum. Acta Physiol. Scand. 1988, 132(2):167-173. 10.1111/j.1748-1716.1988.tb08314.x.
8. Arsenijevic Y., Weiss S. Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor. J. Neurosci. 1998, 18(6):2118-2128.
9. Ayer-le L.C., Stahlbom P.A., Sara V.R. Expression of IGF-1 and -II mRNA in the brain and craniofacial region of the rat fetus. Development 1991, 111(1):105-115.
10. Bach M.A., Shen-Orr Z., Lowe W.L., Roberts C.T., LeRoith D. Insulin-like growth factor I mRNA levels are developmentally regulated in specific regions of the rat brain. Brain Res. Mol. Brain Res. 1991, 10(1):43-48.
11. Baker A.M., Batchelor D.C., Thomas G.B., Wen J.Y., Rafiee M., Lin H., Guan J. Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 2005, 39(2):81-87. 10.1016/j.npep.2004.11.001.
12. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75(1):73-82.
13. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377(9770):1019-1031. 10.1016/S0140-6736(10)61349-9.
14. Ballard F.J., Knowles S.E., Walton P.E., Edson K., Owens P.C., Mohler M.A., Ferraiolo B.L. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. J. Endocrinol. 1991, 128(2):197-204.
15. Ballotti R., Nielsen F.C., Pringle N., Kowalski A., Richardson W.D., Van Obberghen E., Gammeltoft S. Insulin-like growth factor I in cultured rat astrocytes: expression of the gene, and receptor tyrosine kinase. EMBO J. 1987, 6(12):3633-3639.
16. Barker A.J., Ullian E.M. Astrocytes and synaptic plasticity. Neuroscientist 2010, 16(1):40-50. 10.1177/1073858409339215.
17. Batchelor D.C., Lin H., Wen J.Y., Keven C., Van Zijl P.L., Breier B.H., Gluckman P.D., Thomas G.B. Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal. Biochem. 2003, 323(2):156-163.
18. Baxter R.C., Martin J.L., Beniac V.A. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J. Biol. Chem. 1989, 264(20):11843-11848.
19. Beck K.D., Powell-Braxton L., Widmer H.R., Valverde J., Hefti F. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995, 14(4):717-730.
20. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 2011, 1380:42-77. 10.1016/j.brainres.2010.11.078.
21. Bodfish, J.W., Symons, F., Lewis, M.H., 1999. The Repetitive Behavior Scales (RBS). Western Carolina Center Research Reports.
22. Boeckers T.M. The postsynaptic density. Cell Tissue Res. 2006, 326(2):409-422. 10.1007/s00441-006-0274-5.
23. Boeckers T.M., Winter C., Smalla K.H., Kreutz M.R., Bockmann J., Seidenbecher C., Garner C.C., Gundelfinger E.D. Proline-rich synapse-associated proteins ProSAP1 and ProSAP2 interact with synaptic proteins of the SAPAP/GKAP family. Biochem. Biophys. Res. Commun. 1999, 264(1):247-252. 10.1006/bbrc.1999.1489.
24. Boisclair Y.R., Rhoads R.P., Ueki I., Wang J., Ooi G.T. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J. Endocrinol. 2001, 170(1):63-70.
25. Bondy C.A. Transient IGF-I gene expression during the maturation of functionally related central projection neurons. J. Neurosci. 1991, 11(11):3442-3455.
26. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286(5443):1358-1362.
27. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998, 51(2):583-586.
28. Bozdagi O., Sakurai T., Papapetrou D., Wang X., Dickstein D.L., Takahashi N., Kajiwara Y., Yang M., Katz A.M., Scattonia M.L., Harris M.J., Saxena R., Silverman J.L., Crawley J.N., Zhou Q., Hof P.R., Buxbaum J.D. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol. Autism 2010, 1(1):15. 10.1186/2040-2392-1-15.
29. Bozdagi O., Tavassoli T., Buxbaum J.D. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol. Autism 2013, 4(1):9. 10.1186/2040-2392-4-9.
30. Braun K., Segal M. FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb. Cortex 2000, 10(10):1045-1052.
31. Buemi M., Caccamo C., Nostro L., Cavallaro E., Floccari F., Grasso G. Brain and cancer: the protective role of erythropoietin. Med. Res. Rev. 2005, 25(2):245-259. 10.1002/med.20012.
32. Cannella B., Pitt D., Capello E., Raine C.S. Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am. J. Pathol. 2000, 157(3):933-943. 10.1016/S0002-9440(10)64606-8.
33. Cao Y., Gunn A.J., Bennet L., Wu D., George S., Gluckman P.D., Guan J. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J. Cereb. Blood Flow Metab. 2003, 23(6):739-747. 10.1097/01.WCB.0000067720.12805.6F.
34. Caroni P. Activity-sensitive signaling by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system. Ann. N. Y. Acad. Sci. 1993, 692:209-222.
35. Caroni P., Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J. Cell. Biol. 1990, 110(4):1307-1317.
36. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 2002, 8(12):1390-1397. 10.1038/nm793.
37. Carson M.J., Behringer R.R., Brinster R.L., McMorris F.A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993, 10(4):729-740.
38. Castro J., Garcia R.I., Kwok S., Banerjee A., Petravicz J., Woodson J., Mellios N., Tropea D., Sur M. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(27):9941-9946. 10.1073/pnas.1311685111.
39. Cheng C.M., Mervis R.F., Niu S.L., Salem N., Witters L.A., Tseng V., Reinhardt R., Bondy C.A. Insulin-like growth factor 1 is essential for normal dendritic growth. J. Neurosci. Res. 2003, 73(1):1-9. 10.1002/jnr.10634.
40. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Jacobowitz D.M., Kopin I.J. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol. Bull. 1984, 20(3):548-553.
41. Clerk A., Aggeli I.K., Stathopoulou K., Sugden P.H. Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes. Cell. Signal. 2006, 18(2):225-235. 10.1016/j.cellsig.2005.04.005.
42. Collins A.L., Levenson J.M., Vilaythong A.P., Richman R., Armstrong D.L., Noebels J.L., Sweatt J.D., Zoghbi H.Y. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 2004, 13(21):2679-2689. 10.1093/hmg/ddh282.
43. Comery T.A., Harris J.B., Willems P.J., Oostra B.A., Irwin S.A., Weiler I.J., Greenough W.T. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(10):5401-5404.
44. Constantinescu C.S., Farooqi N., O'Brien K., Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 2011, 164(4):1079-1106. 10.1111/j.1476-5381.2011.01302.x.
45. Corvin A.P., Molinos I., Little G., Donohoe G., Gill M., Morris D.W., Tropea D. Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci. Lett. 2012, 520(1):51-56. 10.1016/j.neulet.2012.05.029.
46. Dani V.S., Chang Q., Maffei A., Turrigiano G.G., Jaenisch R., Nelson S.B. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(35):12560-12565. 10.1073/pnas.0506071102.
47. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., Licatalosi D.D., Richter J.D., Darnell R.B. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146(2):247-261. 10.1016/j.cell.2011.06.013.
48. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91(2):231-241.
49. de Pablo F., Perez-Villamil B., Serna J., Gonzalez-Guerrero P.R., Lopez-Carranza A., de la Rosa E.J., Alemany J., Caldes T. IGF-I and the IGF-I receptor in development of nonmammalian vertebrates. Mol. Reprod. Dev. 1993, 35(4):427-432. discussion 432-423. 10.1002/mrd.1080350418.
50. Deacon R.M., Glass L., Snape M., Hurley M.J., Altimiras F.J., Biekofsky R.R., Cogram P. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromol. Med. 2015, 17(1):71-82. 10.1007/s12017-015-8341-2.
51. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175(2):303-317. 10.1006/exnr.2002.7891.
52. Developmental Disabilities Monitoring Network Surveillance Year Principal Investigators, Centers for Disease Control and Prevention Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill. Summ. 2014, 63(2):1-21.
53. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26(22):3279-3290. 10.1038/sj.onc.1210421.
54. Digicaylioglu M., Garden G., Timberlake S., Fletcher L., Lipton S.A. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(26):9855-9860. 10.1073/pnas.0403172101.
55. Divall S.A., Williams T.R., Carver S.E., Koch L., Bruning J.C., Kahn C.R., Wondisford F., Radovick S., Wolfe A. Divergent roles of growth factors in the GnRH regulation of puberty in mice. J. Clin. Invest. 2010, 120(8):2900-2909. 10.1172/JCI41069.
56. Dore S., Krieger C., Kar S., Quirion R. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Brain Res. Mol. Brain Res. 1996, 41(1-2):128-133.
57. Drescher K.M., Murray P.D., Lin X., Carlino J.A., Rodriguez M. TGF-beta 2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis. J. Immunol. 2000, 164(6):3207-3213.
58. Duchen L.W., Strich S.J. An hereditary motor neurone disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'. J. Neurol. Neurosurg. Psychiatry 1968, 31(6):535-542.
59. Durand C.M., Betancur C., Boeckers T.M., Bockmann J., Chaste P., Fauchereau F., Nygren G., Rastam M., Gillberg I.C., Anckarsäter H., Sponheim E., Goubran-Botros H., Delorme R., Chabane N., Mouren-Simeoni M.C., de Mas P., Bieth E., Rogé B., Héron D., Burglen L., Gillberg C., Leboyer M., Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 2007, 39(1):25-27. 10.1038/ng1933.
60. Duron E., Funalot B., Brunel N., Coste J., Quinquis L., Viollet C., Belmin J., Jouanny P., Pasquier F., Treluyer J.M., Epelbaum J., le Bouc Y., Hanon O. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. J. Clin. Endocrinol. Metab. 2012, 97(12):4673-4681. 10.1210/jc.2012-2063.
61. Eberhardt O., Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 2003, 139(2-3):135-151.
62. Ebert A.D., Beres A.J., Barber A.E., Svendsen C.N. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp. Neurol. 2008, 209(1):213-223. 10.1016/j.expneurol.2007.09.022.
63. Escott G.M., Jacobus A.P., Loss E.S. PI3K-dependent actions of insulin and IGF-I on seminiferous tubules from immature rats. Pflugers Arch. 2013, 465(10):1497-1505. 10.1007/s00424-013-1287-z.
64. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13(4):225-239. 10.1038/nrn3209.
65. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23(18):3151-3171. 10.1038/sj.onc.1207542.
66. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23(6):824-854. 10.1210/er.2001-0033.
67. Firth S.M., McDougall F., McLachlan A.J., Baxter R.C. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology 2002, 143(5):1669-1676. 10.1210/endo.143.5.8764.
68. Fischer S., Wiesnet M., Marti H.H., Renz D., Schaper W. Simultaneous activation of several second messengers in hypoxia-induced hyperpermeability of brain derived endothelial cells. J. Cell. Physiol. 2004, 198(3):359-369. 10.1002/jcp.10417.
69. Fletcher L., Kohli S., Sprague S.M., Scranton R.A., Lipton S.A., Parra A., Jimenez D.F., Digicaylioglu M. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J. Neurosurg. 2009, 164-170. 10.3171/2009.2.JNS081199.
70. Anon Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 1994, 78(1):23-33.
71. Frank H.J., Pardridge W.M., Morris W.L., Rosenfeld R.G., Choi T.B. Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes 1986, 35(6):654-661.
72. Frank J.A., Richert N., Lewis B., Bash C., Howard T., Civil R., Stone R., Eaton J., McFarland H., Leist T. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult. Scler. 2002, 8(1):24-29.
73. Freude S., Hettich M.M., Schumann C., Stohr O., Koch L., Kohler C., Udelhoven M., Leeser U., Müller M., Kubota N., Kadowaki T., Krone W., Schröder H., Brüning J.C., Schubert M. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 2009, 23(10):3315-3324. 10.1096/fj.09-132043.
74. Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J. Biol. Chem. 2003, 278(15):13325-13332. 10.1074/jbc.M211398200.
75. Galvez R., Greenough W.T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet. A 2005, 135(2):155-160. 10.1002/ajmg.a.30709.
76. Ganz M.L. The lifetime distribution of the incremental societal costs of autism. Arch. Pediatr. Adolesc. Med. 2007, 161(4):343-349. 10.1001/archpedi.161.4.343.
77. Garber K.B., Visootsak J., Warren S.T. Fragile X syndrome. Eur. J. Hum. Genet. 2008, 16(6):666-672. 10.1038/ejhg.2008.61.
78. Geschwind D.H. Autism: many genes, common pathways?. Cell 2008, 135(3):391-395. 10.1016/j.cell.2008.10.016.
79. Ghezzi P., Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 2004, 11(Suppl. 1):S37-S44. 10.1038/sj.cdd.4401450.
80. Guan J., Waldvogel H.J., Faull R.L., Gluckman P.D., Williams C.E. The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 1999, 89(3):649-659.
81. Gutierrez-Ospina G., Calikoglu A.S., Ye P., D'Ercole A.J. In vivo effects of insulin-like growth factor-I on the development of sensory pathways: analysis of the primary somatic sensory cortex (S1) of transgenic mice. Endocrinology 1996, 137(12):5484-5492. 10.1210/endo.137.12.8940375.
82. Gunnell D., Holly J.M. Hypothesis: do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia?. Schizophr. Res. 2004, 71:191-193.
83. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8(2):61-65. 10.1002/mrdd.10020.
84. Hantai D., Akaaboune M., Lagord C., Murawsky M., Houenou L.J., Festoff B.W., Vaught J.L., Rieger F., Blondet B. Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J. Neurol. Sci. 1995, 129(Suppl):122-126.
85. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(17):9666-9670. 10.1073/pnas.171301998.
86. Harris J.B., Ward M.R. A comparative study of denervation in muscles from mice with inherited progressive neuromuscular disorders. Exp. Neurol. 1974, 42(1):169-180.
87. Hashimoto R., Ono M., Fujiwara H., Higashihashi N., Yoshida M., Enjoh-Kimura T., Sakano K. Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J. Biol. Chem. 1997, 272(44):27936-27942.
88. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18(16):1926-1945. 10.1101/gad.1212704.
89. Hilfiker S., Pieribone V.A., Czernik A.J., Kao H.T., Augustine G.J., Greengard P. Synapsins as regulators of neurotransmitter release. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1999, 354(1381):269-279. 10.1098/rstb.1999.0378.
90. Hodge R.D., D'Ercole A.J., O'Kusky J.R. Insulin-like growth factor-I accelerates the cell cycle by decreasing G1 phase length and increases cell cycle reentry in the embryonic cerebral cortex. J. Neurosci. 2004, 24(45):10201-10210. 10.1523/JNEUROSCI.3246-04.2004.
91. Hoeffer C.A., Sanchez E., Hagerman R.J., Mu Y., Nguyen D.V., Wong H., Whelan A.M., Zukin R.S., Klann E., Tassone F. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012, 11(3):332-341. 10.1111/j.1601-183X.2012.00768.x.
92. Holzenberger M., Leneuve P., Hamard G., Ducos B., Perin L., Binoux M., Le Bouc Y. A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit. Endocrinology 2000, 141(7):2557-2566. 10.1210/endo.141.7.7550.
93. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(11):7746-7750. 10.1073/pnas.122205699.
94. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17(15):1829-1834. 10.1101/gad.1110003.
95. Irwin S.A., Galvez R., Greenough W.T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 2000, 10(10):1038-1044.
96. Johnston M.V., Jeon O.H., Pevsner J., Blue M.E., Naidu S. Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain Dev. 2001, 23(Suppl. 1):S206-213.
97. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16(1):3-34. 10.1210/edrv-16-1-3.
98. Jorntell H., Hansel C. Synaptic memories upside down: bidirectional plasticity at cerebellar parallel fiber-Purkinje cell synapses. Neuron 2006, 52(2):227-238. 10.1016/j.neuron.2006.09.032.
99. Kang Y.J., Digicaylioglu M., Russo R., Kaul M., Achim C.L., Fletcher L., Masliah E., Lipton S.A. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann. Neurol. 2010, 68(3):342-352. 10.1002/ana.22070.
100. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol. Rev. 2011, 91(2):461-553. 10.1152/physrev.00011.2010.
101. Khwaja O.S., Ho E., Barnes K.V., O'Leary H.M., Pereira L.M., Finkelstein Y., Nelson C.A., Vogel-Farley V., DeGregorio G., Holm I.A., Khatwa U., Kapur K., Alexander M.E., Finnegan D.M., Cantwell N.G., Walco A.C., Rappaport L., Gregas M., Fichorova R.N., Shannon M.W., Sur M., Kaufmann W.E. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(12):4596-4601. 10.1073/pnas.1311141111.
102. Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Zoing M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377(9769):942-955. 10.1016/S0140-6736(10) 61156-7.
103. Kim E., Sheng M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 2004, 5(10):771-781. 10.1038/nrn1517.
104. Kolevzon A., Bush L., Wang A.T., Halpern D., Frank Y., Grodberg D., Rapaport R., Tavassoli T., Chaplin W., Soorya L., Buxbaum J.D. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol. Autism 2014, 5(1):54. 10.1186/2040-2392-5-54.
105. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006, 17(4):305-323. 10.1016/j.cytogfr.2006.02.002.
106. Kotani K., Yonezawa K., Hara K., Ueda H., Kitamura Y., Sakaue H., et al. Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling. EMBO J. 1994, 13(10):2313-2321.
107. Kumar V., Zhang M.X., Swank M.W., Kunz J., Wu G.Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 2005, 25(49):11288-11299. 10.1523/JNEUROSCI.2284-05.2005.
108. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy MF, Natter HM, Norris FH,Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997, 49(6):1621-1630.
109. Leblond C.S., Nava C., Polge A., Gauthier J., Huguet G., Lumbroso S., Giuliano F5, Stordeur C6, Depienne C2, Mouzat K3, Pinto D7, Howe J8, Lemière N1, Durand CM1, Guibert J1, Ey E1, Toro R1, Peyre H9, MathieuA1, Amsellem F10, Rastam M11, Gillberg IC12, Rappold GA13, Holt R14, MonacoAP14, Maestrini E15, Galan P16, Heron D17, Jacquette A18, Afenjar A17, Rastetter A2, Brice A2, Devillard F19, Assouline B20, Laffargue F21, LespinasseJ22, Chiesa J23, Rivier F24, Bonneau D25, Regnault B26, Zelenika D27, DelepineM27, Lathrop M27, Sanlaville D28, Schluth-Bolard C28, Edery P28, Perrin L29, Tabet AC29, Schmeisser MJ30, Boeckers TM30, Coleman M31, Sato D8, Szatmari P8, Scherer SW8, Rouleau GA32, Betancur C33, Leboyer M34, Gillberg C35, DelormeR36, Bourgeron T. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014, 10(9):e1004580. 10.1371/journal.pgen.1004580.
110. Lee W.H., Michels K.M., Bondy C.A. Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. Neuroscience 1993, 53(1):251-265.
111. Lewis M.E., Neff N.T., Contreras P.C., Stong D.B., Oppenheim R.W., Grebow P.E., Vaught J.L. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993, 124(1):73-88. 10.1006/exnr.1993.1177.
112. Li W., Quigley L., Yao D.L., Hudson L.D., Brenner M., Zhang B.J., Brocke S., McFarland H.F., Webster H.D. Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects. J. Neuropathol. Exp. Neurol. 1998, 57(5):426-438.
113. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75(1):59-72.
114. Luikenhuis S., Giacometti E., Beard C.F., Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(16):6033-6038. 10.1073/pnas.0401626101.
115. Maile L.A., Holly J.M. Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm. IGF Res. 1999, 9(2):85-95. 10.1054/ghir.1999.0096.
116. Marks J.L., Porte D., Baskin D.G. Localization of type I insulin-like growth factor receptor messenger RNA in the adult rat brain by in situ hybridization. Mol. Endocrinol. 1991, 5(8):1158-1168. 10.1210/mend-5-8-1158.
117. McIlroy J., Chen D., Wjasow C., Michaeli T., Backer J.M. Specific activation of p85-p110 phosphatidylinositol 3'-kinase stimulates DNA synthesis by ras- and p70 S6 kinase-dependent pathways. Mol. Cell. Biol. 1997, 17(1):248-255.
118. McKinnon R.D., Piras G., Ida J.A., Dubois-Dalcq M. A role for TGF-beta in oligodendrocyte differentiation. J. Cell. Biol. 1993, 121(6):1397-1407.
119. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36(6):320-328. 10.1016/j.tibs.2011.03.006.
120. Micheva K.D., Busse B., Weiler N.C., O'Rourke N., Smith S.J. Single-synapse analysis of a diverse synapse population: proteomic imaging methods and markers. Neuron 2010, 68(4):639-653. 10.1016/j.neuron.2010.09.024.
121. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31(2):224-243. 10.1016/j.neurobiolaging.2008.04.002.
122. Mozell R.L., McMorris F.A. Insulin-like growth factor-I stimulates regeneration of oligodendrocytes in vitro. Ann. N. Y. Acad. Sci. 1988, 540:430-432.
123. Murialdo G., Barreca A., Nobili F., Rollero A., Timossi G., Gianelli M.V., Copello F., Rodriguez G., Polleri A. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J. Endocrinol. Invest. 2001, 24(3):139-146. 10.1007/BF03343833.
124. Murphy M.P., LeVine H. Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 2010, 19(1):311-323. 10.3233/JAD-2010-1221.
125. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cognit. Disord. 1999, 10(6):446-451. 17188.
126. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2005, 235(1-2):61-68. 10.1016/j.jns.2005.04.011.
127. Nagano I., Shiote M., Murakami T., Kamada H., Hamakawa Y., Matsubara E., Yokoyama M., Moritaz K., Shoji M., Abe K. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 2005, 27(7):768-772. 10.1179/016164105X39860.
128. Neff N.T., Prevette D., Houenou L.J., Lewis M.E., Glicksman M.A., Yin Q.W., Oppenheim R.W. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J. Neurobiol. 1993, 24(12):1578-1588. 10.1002/neu.480241203.
129. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Jelliffe L.L., Hansen R.L., Phillips T.M. Neuropeptides and neurotrophins in neonatal blood of children with autism ormental retardation. Ann. Neurol. 2001, 49:597-606.
130. Nishijima T., Piriz J., Duflot S., Fernandez A.M., Gaitan G., Gomez-Pinedo U., Verdugo J.M., Leroy F., Soya H., Nuñez A., Torres-Aleman I. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010, 67(5):834-846. 10.1016/j.neuron.2010.08.007.
131. Pan W., Kastin A.J. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 2000, 72(3):171-178. 54584.
132. Papadakis M.A., Grady D., Tierney M.J., Black D., Wells L., Grunfeld C. Insulin-like growth factor 1 and functional status in healthy older men. J. Am. Geriatr. Soc. 1995, 43(12):1350-1355.
133. Pardridge W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997, 17(7):713-731. 10.1097/00004647-199707000-00001.
134. Patel A.B., Loerwald K.W., Huber K.M., Gibson J.R. Postsynaptic FMRP promotes the pruning of cell-to-cell connections among pyramidal neurons in the L5A neocortical network. J. Neurosci. 2014, 34(9):3413-3418. 10.1523/JNEUROSCI.2921-13.2014.
135. Pende M., Um S.H., Mieulet V., Sticker M., Goss V.L., Mestan J., Mueller M., Fumagalli S., Kozma S.C., Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 2004, 24(8):3112-3124.
136. Perez-Villamil B., de la Rosa E.J., Morales A.V., de Pablo F. Developmentally regulated expression of the preproinsulin gene in the chicken embryo during gastrulation and neurulation. Endocrinology 1994, 135(6):2342-2350. 10.1210/endo.135.6.7988416.
137. Pilpel Y., Kolleker A., Berberich S., Ginger M., Frick A., Mientjes E., Oostra B.A., Seeburg P.H. Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice. J. Physiol. 2009, 587(Pt. 4):787-804. 10.1113/jphysiol.2008.160929.
138. Popken G.J., Hodge R.D., Ye P., Zhang J., Ng W., O'Kusky J.R., D'Ercole A.J. In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system. Eur. J. Neurosci. 2004, 19(8):2056-2068. 10.1111/j.0953-816X.2004.03320.x.
139. Prager D., Melmed S. Insulin and insulin-like growth factor I receptors: are there functional distinctions?. Endocrinology 1993, 132(4):1419-1420. 10.1210/endo.132.4.8462444.
140. Rechler M.M., Nissley S.P. The nature and regulation of the receptors for insulin-like growth factors. Annu. Rev. Physiol. 1985, 47:425-442. 10.1146/annurev.ph.47.030185.002233.
141. Reinhardt R.R., Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994, 135(5):1753-1761. 10.1210/endo.135.5.7525251.
142. Riikonen R. Insulin-like growth factor delivery across the blood-brain barrier. Potential use of IGF-1 as a drug in child neurology. Chemotherapy 2006, 6:279-281. 10.1159/000095957.
143. Rinderknecht E., Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J. Biol. Chem. 1978, 253(8):2769-2776.
144. Roberts R.O., Geda Y.E., Knopman D.S., Cha R.H., Pankratz V.S., Boeve B.F., Ivnik R.J., Tangalos E.G., Petersen R.C., Rocca W.A. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008, 30(1):58-69. 10.1159/000115751.
145. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2001, 22(2):117-139.
146. Rosenbloom A.L. The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr. Opin. Pediatr. 2007, 19(4):458-464. 10.1097/MOP.0b013e3282094126.
147. Roussignol G., Ango F., Romorini S., Tu J.C., Sala C., Worley P.F., Bockaert J., Fagni L. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J. Neurosci. 2005, 25(14):3560-3570. 10.1523/JNEUROSCI.4354-04.2005.
148. Sakai Y., Shaw C.A., Dawson B.C., Dugas D.V., Al-Mohtaseb Z., Hill D.E., Zoghbi H.Y. Protein interactome reveals converging molecular pathways among autism disorders. Sci. Transl. Med. 2011, 3(86):86ra49. 10.1126/scitranslmed.3002166.
149. Sara V.R., Carlsson-Skwirut C., Drakenberg K., Giacobini M.B., Håkansson L., Mirmiran M., Nordberg A., Olson L., Reinecke M., Ståhlbom P.A., Sandberg Nordqvist A.C. The biological role of truncated insulin-like growth factor-1 and the tripeptide GPE in the central nervous system. Ann. N. Y. Acad. Sci. 1993, 692:183-191.
150. Sara V.R., Hall K. The somatomedins throughout development. Bull Schweiz. Akad. Med. Wiss. 1981, 199-203.
151. Segal I., Korkotian I., Murphy D.D. Dendritic spine formation and pruning: common cellular mechanisms?. Trends Neurosci. 2000, 23(2):53-57.
152. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 1990, 527(1):7-20.
153. Sevigny J.J., Ryan J.M., van Dyck C.H., Peng Y., Lines C.R., Nessly M.L., M.K.P.S.Group Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008, 71(21):1702-1708. 10.1212/01.wnl.0000335163.88054.e7.
154. Shcheglovitov A., Shcheglovitova O., Yazawa M., Portmann T., Shu R., Sebastiano V., Dolmetsch R.E. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 2013, 503(7475):267-271. 10.1038/nature12618.
155. Sheng M., Kim E. The Shank family of scaffold proteins. J. Cell Sci. 2000, 113(Pt. 11):1851-1856.
156. Soorya L., Kolevzon A., Zweifach J., Lim T., Dobry Y., Schwartz L., Frank Y., Wang A.T., Cai G., Parkhomenko E., Halpern D., Grodberg D., Angarita B., Willner J.P., Yang A., Canitano R., Chaplin W., Betancur C., Buxbaum J.D. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency, Mol. Autism 2013, 4(1):18. 10.1186/2040-2392-4-18.
157. Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C.A., McCluskey L.F., Nash S., Newman D.S., Pascuzzi R.M., Pioro E., Sams L.J., Scelsa S., Simpson E.P., Subramony S.H., Tiryaki E., Thornton C.A. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71(22):1770-1775. 10.1212/01.wnl.0000335970.78664.36.
158. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 2004, 14(3):395-403.
159. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77(4):1037-1048.
160. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127(2):481-496. 10.1016/j.neuroscience.2004.05.029.
161. Tomas F.M., Knowles S.E., Owens P.C., Read L.C., Chandler C.S., Gargosky S.E., Ballard F.J. Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J. Endocrinol. 1991, 128(1):97-105.
162. Torres-Aleman I., Naftolin F., Robbins R.J. Trophic effects of insulin-like growth factor-I on fetal rat hypothalamic cells in culture. Neuroscience 1990, 35(3):601-608.
163. Torres-Aleman I., Villalba M., Nieto-Bona M.P. Insulin-like growth factor-I modulation of cerebellar cell populations is developmentally stage-dependent and mediated by specific intracellular pathways. Neuroscience 1998, 83(2):321-334.
164. Tropea D., Giacometti E., Wilson N.R., Beard C., McCurry C., Fu D.D., Flannery R., Jaenisch R., Sur M. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(6):2029-2034. 10.1073/pnas.0812394106.
165. Twigg S.M., Baxter R.C. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J. Biol. Chem. 1998, 273(11):6074-6079.
166. Vanhala R., Turpeinen U., Riikonen R. Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. Dev. Med. Child Neurol. 2001, 43(9):614-616.
167. Volterra A., Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat. Rev. Neurosci. 2005, 6(8):626-640. 10.1038/nrn1722.
168. Waga C., Asano H., Sanagi T., Suzuki E., Nakamura Y., Tsuchiya A., Itoh M., Goto Y., Kohsaka S., Uchino S. Identification of two novel Shank3 transcripts in the developing mouse neocortex. J. Neurochem. 2014, 128(2):280-293. 10.1111/jnc.12505.
169. Walton P.E., Dunshea F.R., Ballard F.J. In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness. Prog. Growth Factor Res. 1995, 6(2-4):385-395.
170. Wang L., Yang H.J., Xia Y.Y., Feng Z.W. Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3beta/JNK signaling. Apoptosis 2010, 15(12):1470-1479. 10.1007/s10495-010-0547-z.
171. Watanabe T., Miyazaki A., Katagiri T., Yamamoto H., Idei T., Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J. Am. Geriatr. Soc. 2005, 53(10):1748-1753. 10.1111/j.1532-5415.2005.53524.x.
172. Wymann M.P., Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1998, 1436(1-2):127-150.
173. Xu G.J., Cai S., Wu J.B. Effect of insulin-like growth factor-1 on bone morphogenetic protein-2 expression in hepatic carcinoma SMMC7721 cells through the p38 MAPK signaling pathway. Asian Pac. J. Cancer Prev. 2012, 13(4):1183-1186.
174. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(13):7324-7329.
175. Yamamoto H., Murphy L.J. Generation of des-(1-3) insulin-like growth factor-I in serum by an acid protease. Endocrinology 1994, 135(6):2432-2439. 10.1210/endo.135.6.7988428.
176. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49(7):1053-1066. 10.1016/j.neuropharm.2005.06.004.
177. Ye P., Carson J., D'Ercole A.J. In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J. Neurosci. 1995, 15(11):7344-7356.
178. Ye P., Li L., Richards R.G., DiAugustine R.P., D'Ercole A.J. Myelination is altered in insulin-like growth factor-I null mutant mice. J. Neurosci. 2002, 22(14):6041-6051. 20026581.
179. Ye P., Popken G.J., Kemper A., McCarthy K., Popko B., D'Ercole A.J. Astrocyte-specific overexpression of insulin-like growth factor-I promotes brain overgrowth and glial fibrillary acidic protein expression. J. Neurosci. Res. 2004, 78(4):472-484. 10.1002/jnr.20288.
180. Zeger M., Popken G., Zhang J., Xuan S., Lu Q.R., Schwab M.H., Nave K.A., Rowitch D., D'Ercole A.J., Ye P. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007, 55(4):400-411. 10.1002/glia.20469.